Quick Answer
Theravance Biopharma, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $107.46 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +66.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Theravance Biopharma, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 120.9%.
- Historical annual values: Fiscal year 2025: $107.46 million | Fiscal year 2024: $64.38 million | Fiscal year 2023: $57.42 million | Fiscal year 2022: $51.35 million | Fiscal year 2021: $55.31 million | Fiscal year 2020: $71.86 million | Fiscal year 2019: $73.41 million | Fiscal year 2018: $60.37 million | Fiscal year 2017: $15.39 million | Fiscal year 2016: $48.65 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: